Patents by Inventor Mary Joyce CLARK

Mary Joyce CLARK has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Beta-2 selective adrenergic receptor agonists
    Patent number: 11590089
    Abstract: Aspects of the present disclosure include conformationally restricted analogs of catecholamine type compounds (e.g., isoprenaline, adrenaline, noradrenaline) which activate ?2AR with high selectivity over ?1AR. The subject beta-2 selective adrenergic receptor agonist compounds may serve as bronchiodilators and find use in the treatment of a variety of bronchoconstrictive diseases and conditions. Also provided are compositions and methods for treating preterm labor. A method of treating acute asthma including administration of a subject compound to a subject in need thereof is provided. The subject method can provide for reduced undesirable side effects associated with non-selective ?-adrenergic receptor agonism, such as inotropic and chronotropic effects that leads to elevated blood pressure. The compounds can also be used to prevent or treat heart failure. Kits and compositions for practicing the subject methods are also provided.
    Type: Grant
    Filed: November 30, 2018
    Date of Patent: February 28, 2023
    Assignees: THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY, THE REGENTS OF THE UNIVERSITY OF CALIFORNIA, FRIEDRICH-ALEXANDER-UNIVERSITÄT ERLANGEN-NÜRNBERG
    Inventors: Roger Sunahara, Harald Huebner, Jeremy Shonberg, Anne Stößel, Markus Stanek, Dorothée Möller, Mary Joyce Clark, Brian K. Kobilka, Peter Gmeiner, Luis Maul
  • BETA-2 SELECTIVE ADRENERGIC RECEPTOR AGONISTS
    Publication number: 20200360304
    Abstract: Aspects of the present disclosure include conformationally restricted analogs of catecholamine type compounds (e.g., isoprenaline, adrenaline, noradrenaline) which activate ?2AR with high selectivity over ?1AR. The subject beta-2 selective adrenergic receptor agonist compounds may serve as bronchiodilators and find use in the treatment of a variety of bronchoconstrictive diseases and conditions. Also provided are compositions and methods for treating preterm labor. A method of treating acute asthma including administration of a subject compound to a subject in need thereof is provided. The subject method can provide for reduced undesirable side effects associated with non-selective ?-adrenergic receptor agonism, such as inotropic and chronotropic effects that leads to elevated blood pressure. The compounds can also be used to prevent or treat heart failure. Kits and compositions for practicing the subject methods are also provided.
    Type: Application
    Filed: November 30, 2018
    Publication date: November 19, 2020
    Inventors: Roger SUNAHARA, Harald HUEBNER, Jeremy SHONBERG, Anne STÖßEL, Markus STANEK, Dorothée MÖLLER, Mary Joyce CLARK, Brian K. KOBILKA, Peter GMEINER, Luis MAUL
  • FLUOROPHENYL SUBSTITUTED MUSCARINIC RECEPTOR LIGANDS WITH SELECTIVITY FOR M3 OVER M2
    Publication number: 20200308168
    Abstract: The present invention relates to fluorophenyl substituted muscarinic receptor ligands with selectivity for M3 over M2 and to the use of these compounds in the treatment of various diseases such as asthma, chronic obstructive pulmonary disease (COPD), bronchopulmonary dysplasia (BPD) and urinary incontinence.
    Type: Application
    Filed: December 3, 2018
    Publication date: October 1, 2020
    Applicants: Friedrich-Alexander-Universität Erlangen-Nürnberg, The Board of Trustees of the Leland Stanford Junior University, The Regents of the University of California
    Inventors: Ashutosh BANERJEE, Amelie BARTUSCHAT, Katrin EITEL, Peter GMEINER, Markus HEINRICH, Josefa HOFMANN, Harald HÜBNER, Hannelore RAMPP, Benjamin SCHAAKE, Brian KOBILKA, Roger SUNAHARA, Mary Joyce CLARK, Inbar FISH, Brian SHOICHET